Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Gilead Sciences, Inc. GILD
$77.94
-$0.75 (-0.97%)
На 18:00, 12 мая 2023
+0.80%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
97205986747.00000000
-
week52high
89.74
-
week52low
57.17
-
Revenue
27281000000
-
P/E TTM
54
-
Beta
0.39896100
-
EPS
4.37000000
-
Last Dividend
3.00000000
-
Next Earnings Date
31 июл 2023 г. в 10:59
Описание компании
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | Neutral | 26 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| Cantor Fitzgerald | Neutral | 13 июл 2022 г. | |
| SVB Leerink | Market Perform | 23 мая 2022 г. | |
| Piper Sandler | Neutral | Neutral | 17 мая 2022 г. |
| Truist Securities | Hold | Hold | 15 сент 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 13 сент 2022 г. |
| JP Morgan | Overweight | Neutral | 04 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 13 окт 2022 г. |
| Barclays | Underweight | Underweight | 12 окт 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| RBC Capital | Outperform | Outperform | 28 окт 2022 г. |
| Piper Sandler | Overweight | Neutral | 28 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 01 ноя 2022 г. |
| Maxim Group | Buy | Buy | 31 окт 2022 г. |
| Barclays | Equal-Weight | Underweight | 31 окт 2022 г. |
| Mizuho | Buy | Buy | 08 ноя 2022 г. |
| Cowen & Co. | Outperform | Outperform | 08 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 01 дек 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 03 янв 2023 г. |
| RBC Capital | Sector Perform | Outperform | 03 янв 2023 г. |
| Piper Sandler | Overweight | Overweight | 19 янв 2023 г. |
| Barclays | Equal-Weight | Equal-Weight | 18 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mercier Johanna | D | 76365 | 15325 | 24 янв 2023 г. |
| Mercier Johanna | A | 91690 | 38270 | 24 янв 2023 г. |
| Mercier Johanna | A | 53420 | 29124 | 24 янв 2023 г. |
| Dickinson Andrew D | D | 103956 | 15327 | 24 янв 2023 г. |
| Dickinson Andrew D | A | 119283 | 38270 | 24 янв 2023 г. |
| Dickinson Andrew D | A | 81013 | 27932 | 24 янв 2023 г. |
| O'Day Daniel Patrick | D | 352975 | 59078 | 24 янв 2023 г. |
| O'Day Daniel Patrick | A | 412053 | 136647 | 24 янв 2023 г. |
| O'Day Daniel Patrick | A | 275406 | 78370 | 24 янв 2023 г. |
| Parsey Merdad | D | 82738 | 17749 | 24 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 35356500 | -299153 | 31 авг 2020 г. |
| Vanguard 500 Index Fund | 25767900 | -91492 | 31 авг 2020 г. |
| American Funds Capital Income Builder | 30288000 | 3849500 | 30 июн 2020 г. |
| American Funds American Mutual Fund | 28969500 | 4233800 | 30 июн 2020 г. |
| American Funds Investment Company of America | 27283100 | 4211600 | 30 июн 2020 г. |
| American Funds Washington Mutual Investors Fund | 22966700 | -1974000 | 30 июн 2020 г. |
| American Funds Growth Fund of America | 18506100 | 8880100 | 30 июн 2020 г. |
| American Funds American Balanced Fund | 18214500 | 1964700 | 30 июн 2020 г. |
| American Funds Income Fund of America | 16134000 | 369000 | 30 июн 2020 г. |
| American Funds Capital World Growth & Income Fund | 15830300 | 1998300 | 30 июн 2020 г. |
Новостная лента
Gilead Sciences Stock: Bear vs. Bull
The Motley Fool
12 мая 2023 г. в 05:30
Declining sales of certain drugs, including coronavirus treatment Veklury, has weighed on Gilead's earnings. Still, Gilead is the world's leader in HIV treatments -- and new products across treatment areas could boost growth down the road.
Gilead Sciences didn't violate government patents on HIV prevention treatment, jury finds
CNBC
09 мая 2023 г. в 12:43
Final Trades: Chevron, American Express & Gilead
CNBC Television
05 мая 2023 г. в 15:02
The "Halftime Report" traders give their top picks to watch for the second half.
2 Magnificent Dividend Stocks to Buy Before the Next Recession
The Motley Fool
05 мая 2023 г. в 09:45
Both of these drugmakers have rich pipelines that will allow them to recover from recent sales slumps. They also offer above-average dividend yields and have raised their payouts regularly over the last five years.
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
The Motley Fool
04 мая 2023 г. в 07:50
Gilead Sciences stock hasn't been a good investment in recent years, often underperforming the S&P 500. Declining revenue and a lack of a growth catalyst has made investors bearish on the stock.